Executives from the generic and biotech drug industries are expected to spar on Capitol Hill Wednesday over the potential risks and benefits of allowing generic drug companies to market cheaper versions of biotech drugs.Representatives from generic drug maker Barr Pharmaceuticals Inc. and biotech company Genentech Inc. are among the panelists scheduled to testify at a House Energy and Commerce Committee hearing. At stake is whether the government should allow generic versions of biotech drugs, which are some of the most costly medical treatments. A leading Food and Drug Administration official also is scheduled to speak.>>> Discuss This Story
